EFFECT OF DETOX AS AN ADJUVANT FOR MELANOMA VACCINE

被引:30
作者
SCHULTZ, N
ORATZ, R
CHEN, DL
ZELENIUCHJACQUOTTE, A
ABELES, G
BYSTRYN, JC
机构
[1] NYU,MED CTR,RONALD O PERELMAN DEPT DERMATOL,NEW YORK,NY 10016
[2] NYU,MED CTR,DEPT MED,NEW YORK,NY 10016
[3] KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016
关键词
MELANOMA; VACCINE; ADJUVANT; ANTIBODIES; DETOX; ANTIGENS; IMMUNIZATION;
D O I
10.1016/0264-410X(94)00003-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The identification of effective adjuvants is critical for tumor vaccine development. Towards the end, we examined whether the immunogenicity of a melanoma vaccine could be potentiated by DETOX(TM), an adjuvant consisting of monophosphoryl lipid A (MPL) and purified mycobacterial cell-wall skeleton (CWS). Nineteen patients with resected stage III melanoma were immunized with a polyvalent melanoma antigen vaccine (40 mu g) admixed with DETOX(TM), q3 wks x 4. Seven patients received vaccine + low-dose DETOX(TM) (10 mu g MPL + 100 mu g CWS) and 12 received vaccine + high-dose DETOX(TM) (20 mu g MPL + 200 mu g CWS). A non-randomized control group of 35 patients was treated similarly with 40 mu g vaccine + alum. One week after the fourth vaccine immunization, melanoma antibodies were increased over baseline in 7/7 (100%) patients treated with vaccine + low-dose DETOX(TM), 8/12 (67%) patients treated with vaccine + high-dose DETOX, and in 4/19 (21%) of vaccine + alum patients. For the entire DETOX group, the antibody response rate was 15/19 (79%) compared 4/19 (21%) in the alum group (p<0.001). In contrast, a strong delayed-type hypersensitivity (DTH) response (greater than or equal to 15 mm increase in DTH response over baseline) was induced in 50% of the entire DETOX(TM) group versus in 47% of the alum group. Median disease-free (DF) survival for the entire DETOX(TM) group was 17.8 months compared with 32.1 months in the alum group (p<0.05). In conclusion, DETOX(TM) markedly potentiated antibody but had little effect on DTH responses to melanoma vaccine immunization. It did not appear to improve disease-free survival in comparison in this non-randomized study.
引用
收藏
页码:503 / 508
页数:6
相关论文
共 33 条
  • [1] NONSPECIFIC AND SPECIFIC ACTIVE IMMUNOTHERAPY IN A B-16 MURINE MELANOMA SYSTEM
    AVENT, J
    VERVAERT, C
    SEIGLER, HF
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1979, 12 (01) : 87 - 96
  • [2] ADJUVANTICITY OF MYCOBACTERIAL CELL WALLS
    AZUMA, I
    KISHIMOTO, S
    YAMAMURA, Y
    PETIT, JF
    [J]. JAPANESE JOURNAL OF MICROBIOLOGY, 1971, 15 (02): : 193 - +
  • [3] BERD D, 1986, CANCER RES, V46, P2572
  • [4] BYSTRYN JC, 1992, CANCER RES, V52, P5948
  • [5] BYSTRYN JC, 1992, CANCER-AM CANCER SOC, V69, P1157, DOI 10.1002/cncr.2820690516
  • [6] BYSTRYN JC, 1978, J IMMUNOL, V120, P96
  • [7] TUMOR VACCINES
    BYSTRYN, JC
    [J]. CANCER AND METASTASIS REVIEWS, 1990, 9 (01) : 81 - 91
  • [8] BYSTRYN JC, 1986, J BIOL RESP MODIF, V5, P221
  • [9] CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO
  • [10] 2-4